Cancer Family
Peritoneal Neoplasm
CI-CAN-00000318Explore in graph →
Non-malignant142 active trials5 approved drugs2 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000318Explore in graph →
Clinical trials
592 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01294293 | TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | completed | Phase 1 | 20 | Gynecologic Oncology GroupNETWORK | 1 | Dec 25, 2014 | clinicaltrials |
| NCT00868192 | Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian Primary Peritoneal Carcinoma | completed | Phase 2 | 38 | Washington University School of MedicineOTHER | 1 | Oct 20, 2014 |
| clinicaltrials |
| NCT00003120 | S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission | completed | Phase 3 | 308 | SWOG Cancer Research NetworkNETWORK | 1 | Oct 9, 2014 | clinicaltrials |
| NCT00550784 | Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 1 | 8 | City of Hope Medical CenterOTHER | 0 | Oct 7, 2014 | clinicaltrials |
| NCT01104675 | Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer | completed | Phase 2 | 64 | CASI pharmaceuticals, Inc.INDUSTRY | 2 | Aug 6, 2014 | clinicaltrials |
| NCT00850772 | Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer(OPEN) | completed | Phase 3 | 109 | Queensland Centre for Gynaecological CancerOTHER_GOV | 1 | Jun 12, 2014 | clinicaltrials |
| NCT00183794 | Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma | completed | Phase 2 | 20 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00436644 | Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin | completed | Phase 2 | 18 | Mayo ClinicOTHER | 1 | Apr 16, 2014 | clinicaltrials |
| NCT00666991 | Pharmacokinetic, Safety and Efficacy Study of Nanoparticle Paclitaxel in Patients With Peritoneal Cancers | completed | Phase 1 | 22 | CritiTech, Inc.INDUSTRY | 1 | Feb 27, 2014 | clinicaltrials |
| NCT00698451 | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers | completed | Phase 2 | 54 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 1 | Sep 6, 2013 | clinicaltrials |
| NCT00003944 | Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 3 | Fox Chase Cancer CenterOTHER | 1 | Apr 17, 2013 | clinicaltrials |
| NCT00683241 | A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer | completed | Phase 1 | 36 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 26, 2013 | clinicaltrials |
| NCT00083928 | Efficacy of Å6 in Ovarian Cancer Patients Following First-Line Chemotherapy and a Rising CA125 Levels | completed | Phase 2 | 60 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00003896 | S9912 Combination Chemo in Stage III Ovarian Cancer, | completed | Phase 2 | 68 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 4, 2013 | clinicaltrials |
| NCT00491855 | Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 3, 2013 | clinicaltrials |
| NCT00672295 | PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer | completed | Phase 1 | 11 | AA SecordOTHER | 1 | Dec 28, 2012 | clinicaltrials |
| NCT00004081 | Docetaxel in Treating Women With Ovarian Epithelial or Primary Peritoneal Cancer | completed | Phase 2 | 30 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 13, 2012 | clinicaltrials |
| NCT00501644 | Chemoimmunotherapy Study for Patients With Epithelial Ovarian Cancer | completed | Phase 2 | 59 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 7, 2012 | clinicaltrials |
| NCT00004895 | Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery | completed | Phase 2 | — | Northwestern UniversityOTHER | 1 | Jun 6, 2012 | clinicaltrials |
| NCT00035100 | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer | completed | Phase 2 | 54 | Novartis PharmaceuticalsINDUSTRY | 5 | Apr 16, 2012 | clinicaltrials |
| NCT00407563 | Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer | completed | Phase 2 | 48 | Accelerated Community Oncology Research NetworkOTHER | 1 | Apr 5, 2012 | clinicaltrials |
| NCT00436657 | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer | completed | Phase 1 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 2, 2012 | clinicaltrials |
| NCT00561795 | Feasibility Study of Pazopanib in Combination With Chemotherapy in Gynaecological Tumors | completed | Phase 2 | 12 | GlaxoSmithKlineINDUSTRY | 2 | Mar 22, 2012 | clinicaltrials |
| NCT00245050 | Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Cancer | completed | Phase 3 | 34 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 30, 2011 | clinicaltrials |
| NCT00332696 | Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis | completed | Phase 2 | 64 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 23, 2011 | clinicaltrials |
| NCT01048814 | Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases | completed | — | 512 | Precision TherapeuticsINDUSTRY | 1 | Jun 3, 2011 | clinicaltrials |
| NCT00005049 | Combination Chemotherapy in Treating Patients With Stage III Ovarian Epithelial Cancer or Gastrointestinal Cancer | completed | Phase 2 | 45 | NYU Langone HealthOTHER | 1 | Apr 6, 2011 | clinicaltrials |
| NCT00006391 | Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 1 | — | NYU Langone HealthOTHER | 1 | Apr 5, 2011 | clinicaltrials |
| NCT00191646 | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy | completed | Phase 3 | 919 | Eli Lilly and CompanyINDUSTRY | 2 | Mar 4, 2011 | clinicaltrials |
| NCT00517621 | Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire | completed | Phase 2 | 100 | ARCAGY/ GINECO GROUPOTHER | 1 | Feb 25, 2011 | clinicaltrials |
| NCT00217529 | Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer | completed | Phase 1 / Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00217555 | Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00217568 | Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer | completed | Phase 2 | — | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 21, 2010 | clinicaltrials |
| NCT00101257 | Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer | completed | Phase 1 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | May 7, 2010 | clinicaltrials |
| NCT00063401 | Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer | completed | Phase 2 | 39 | Eli Lilly and CompanyINDUSTRY | 1 | Apr 8, 2010 | clinicaltrials |
| NCT00461786 | A Study of Single Agent Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer | completed | Phase 2 | 51 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 4, 2009 | clinicaltrials |
| NCT00001332 | Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001569 | Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis | completed | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00006155 | SU5416 and Carboplatin to Treat Ovarian Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00191607 | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. | completed | Phase 3 | 162 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
| NCT00074867 | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tube Cancer | completed | Phase 2 | 29 | PfizerINDUSTRY | 2 | Nov 7, 2006 | clinicaltrials |
| NCT00103545 | Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response | completed | Phase 1 / Phase 2 | 36 | AGO Study GroupOTHER | 1 | Oct 2, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Dec 25, 2014source: clinicaltrials